Results 81 to 90 of about 65,300 (300)
, 2009 Poly(ethylene glycol)s (PEGs) are potential drug carriers for improving the therapeutic index of anticancer agents. In this work, a novel methodology for constructing PEG prodrug of anthracycline anticancer drugs was developed based on N-Mannich base of ...
Zhao, Yong-Jiang +8 more
core +1 more source
Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses [PDF]
, 2012 Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Hartley, J.A. +47 more
core +1 more source
Inhibitory Prodrug Approach for Selective Elimination of Immunosuppressive M2 Macrophages
, 2022 Tumor associated macrophages (TAMs) support tumor development and have emerged as important regulators of therapeutic response to cytostatic agents. To target TAMs, we have developed a novel drug delivery approach which induces drug release in response ...
Martijn, Verdoes +1 more
core +1 more source
Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies
Advanced Science, EarlyView.In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang +4 more
wiley +1 more source
Conditions for safe and effective ADEPT treatment
, 2010 Antibody directed enzyme prodrug therapy (ADEPT) is a drug delivery system developed for the treatment of cancer. ADEPT uses a systemically administered antibody, tethered to an enzyme, to localize enzyme in tumour deposits.
Wilkins, D.K.
core
Use of a direct, positive selection strategy to generate improved prodrug-activating enzymes for cancer gene therapy [PDF]
, 2011 E. coli NfsB nitroreductase (NTR) is currently being studied in combination with the prodrug CB1954, as a gene directed enzyme prodrug therapy. NTR reduces CB1954 at either the 2- or 4-nitro groups to produce highly cytotoxic hydroxylamine derivatives ...
Baker, Shelley Louise
core
Advanced Science, EarlyView.An implantable phototriggered prodrug depot patch (iPDP) is presented that enables actively programmable drug release post‐implantation. Covalently conjugated prodrug ensures minimal leakage; illumination parameters serve as a code to precisely control dose per release.
Haipeng Lu +10 more
wiley +1 more source
Studies Towards a pH-Sensitive Anticancer Prodrug Model
, 2010 Tumour-activated prodrug (TAP) is designed to aim at increasing the prodrug selectivity to kill cancer cells. One strategy to is to design a TAP containing an amine cytotoxin, present as an amide function, which could be released more rapidly in the low ...
Teng, Xiao Shi
core
The protide prodrug technology: Where next? [PDF]
, 2019 The ProTide prodrug technology has proved very useful in the discovery of nucleotide therapeutics and has successfully led to two FDA-approved drugs. However, with the extensive application of this prodrug approach to nucleotides for nearly three decades,
Mehellou, Youcef +2 more
core +1 more source
Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles
Advanced NanoBiomed Research, EarlyView.This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley +1 more source